

10/14 Discussion Question:

Question 1) Considering the information presented today and at the meeting of the VRBPAC on September 17, 2021, including updated information on effectiveness of mRNA COVID-19 vaccines, please discuss whether available data support use of a mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) booster dose administered at least 6 months after completion of the same mRNA COVID-19 vaccine primary series in the general population of adults in an age group less than 65 years.

- For the purposes of this question, age groups below 18 years should not be considered